Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJacalyn RosenblattSASyed Abbas AliEGEli Gabayan

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows 50-70% response rate with elranatamab and nirogacestat in relapsed myeloma, suggesting further investigation is needed.

Key Points

  • Response rates ranged from 50.0% to 70.0% across five dose levels of elranatamab and nirogacestat.
  • Combination therapy showed an overall objective response rate of 61.8% with manageable toxicity.
  • The safety of the bispecific antibody combined with gamma-secretase inhibitors was carefully assessed.
  • Findings indicate the need for further evaluation of BCMA-targeted therapy with mediators for multiple myeloma.

Cite This Study

Rosenblatt et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da90https://doi.org/10.1182/blood-2025-4058
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 8 citations
  2. 2Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025 · 3 citations
  3. 3Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  4. 4Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  5. 5Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial2025 · 1 citations